MedWatch

Analyst: Positive data ease partner search

New positive data will aid Topotarget in its search for a European partner for a promising candidate drug, says an analyst. Although the price is going up, he still believes that the share is lower than it should be.

New data for candidate drug, Belinostat, published by Danish biotech Topotarget on Thursday will bring with it a number of positive side effects, says analyst Mick Cooper from London, UK-based Edison Investment Research Limited.

The data confirm Belinostat’s potential and increase the likelihood of the drug gaining approval next year. Meanwhile, the positive data are bound to make it easier for Topotarget to find a partner for the drug in Europe.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier